Scholarlink

Background <p>Immune checkpoint inhibitors (ICIs) plus chemotherapy serve as the primary treatment for advanced intrahepatic cholangiocarcinoma (ICC), but they present limited effectiveness. This multicenter study intended to evaluate the feasibility of LRT plus ICIs, chemotherapy, and lenvatinib in patients with advanced ICC.</p> Methods <p>Patients receiving LRT-ICIs-Chemotherapy-Lenvatinib (LRT-ICI-Chemo-Len group, N = 66) or ICIs-Chemotherapy (ICI-Chemo group, N = 81) between April 2020 and May 2025 were enrolled. The study’s outcomes included progression-free survival (PFS), overall survival (OS), tumor response, and adverse events (AEs).</p> Results <p>The LRT-ICI-Chemo-Len group showed notable enhancement in median PFS (9.9&#xa0;months vs. 7.6&#xa0;months, <i>P</i> = 0.004), median OS (20.9&#xa0;months vs. 13.7&#xa0;months, <i>P</i> = 0.004), objective response rate (ORR: 59.1% vs. 27.2%), and disease control rate (DCR: 93.9% vs. 84.0%). Conversion resection was performed in 8/66 (12.1%) in the LRT-ICI-Chemo-Len group, statistically higher than the 2.5% in the ICI-Chemo group. There was no statistically significant difference in the incidence of grade 3-4&#xa0;AE between the LRT-ICI-Chemo-Len group (65.2%) and the ICI-Chemo group (56.8%) (<i>P</i> = 0.389). The most common grade 3-4 AE in the LRT-ICI-Chemo-Len group was myelosuppression. In the ICI-Chemo group, the most frequent grade 3-4&#xa0;AE was myelosuppression. All AEs were manageable, with no grade 5 AE observed.</p> Conclusions <p>Compared with the ICI-Chemo regimen, the LRT-ICI-Chemo-Len regimen significantly improved the prognosis of patients with advanced ICC. There was no significant difference in the incidence of grade 3-4 AEs between the two treatment regimens, and all AEs were manageable. This indicates that the LRT-ICI-Chemo-Len combination regimen is a feasible approach for the first-line treatment of advanced ICC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Mingming Wang,
  • Shuofeng Li,
  • Guanhua Yu,
  • An Zhang,
  • Shikang Ding,
  • Yihong Zhang,
  • Shi Feng,
  • Zixiang Zhou,
  • Mingjian Piao,
  • Weixuan Pan,
  • Chengjie Li,
  • Boyu Sun,
  • Jiongyuan Li,
  • Nan Zhang,
  • Xinyuan Chen,
  • Yongliang Sun,
  • Wen Zhang,
  • Zhenyu Zhu,
  • Haitao Zhao

摘要

Background

Immune checkpoint inhibitors (ICIs) plus chemotherapy serve as the primary treatment for advanced intrahepatic cholangiocarcinoma (ICC), but they present limited effectiveness. This multicenter study intended to evaluate the feasibility of LRT plus ICIs, chemotherapy, and lenvatinib in patients with advanced ICC.

Methods

Patients receiving LRT-ICIs-Chemotherapy-Lenvatinib (LRT-ICI-Chemo-Len group, N = 66) or ICIs-Chemotherapy (ICI-Chemo group, N = 81) between April 2020 and May 2025 were enrolled. The study’s outcomes included progression-free survival (PFS), overall survival (OS), tumor response, and adverse events (AEs).

Results

The LRT-ICI-Chemo-Len group showed notable enhancement in median PFS (9.9 months vs. 7.6 months, P = 0.004), median OS (20.9 months vs. 13.7 months, P = 0.004), objective response rate (ORR: 59.1% vs. 27.2%), and disease control rate (DCR: 93.9% vs. 84.0%). Conversion resection was performed in 8/66 (12.1%) in the LRT-ICI-Chemo-Len group, statistically higher than the 2.5% in the ICI-Chemo group. There was no statistically significant difference in the incidence of grade 3-4 AE between the LRT-ICI-Chemo-Len group (65.2%) and the ICI-Chemo group (56.8%) (P = 0.389). The most common grade 3-4 AE in the LRT-ICI-Chemo-Len group was myelosuppression. In the ICI-Chemo group, the most frequent grade 3-4 AE was myelosuppression. All AEs were manageable, with no grade 5 AE observed.

Conclusions

Compared with the ICI-Chemo regimen, the LRT-ICI-Chemo-Len regimen significantly improved the prognosis of patients with advanced ICC. There was no significant difference in the incidence of grade 3-4 AEs between the two treatment regimens, and all AEs were manageable. This indicates that the LRT-ICI-Chemo-Len combination regimen is a feasible approach for the first-line treatment of advanced ICC.